Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Vaxcyte (PCVX)
TipRanks (Fri, 26-Jun 7:00 AM ET)
Globe Newswire (Tue, 2-Jun 4:05 PM ET)
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Wed, 6-May 4:05 PM ET)
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Globe Newswire (Tue, 7-Apr 4:05 PM ET)
Market Chameleon (Mon, 23-Mar 5:33 AM ET)
Vaxcyte’s $550 Million Public Offering Highlights Expanding Vaccine Ambitions
Market Chameleon (Fri, 30-Jan 3:50 AM ET)
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Vaxcyte trades on the NASDAQ stock market under the symbol PCVX.
As of July 1, 2026, PCVX stock price declined to $57.26 with 180,665 million shares trading.
PCVX has a beta of 0.74, meaning it tends to be less sensitive to market movements. PCVX has a correlation of 0.03 to the broad based SPY ETF.
PCVX has a market cap of $8.27 billion. This is considered a Mid Cap stock.
Last quarter Vaxcyte reported $0 in Revenue and -$2.30 earnings per share. This fell short of revenue expectation by $-13 million and missed earnings estimates by -$.51.
In the last 3 years, PCVX traded as high as $121.06 and as low as $27.66.
The top ETF exchange traded funds that PCVX belongs to (by Net Assets): VTI, IWM, VB, XBI, VBK.
PCVX has outperformed the market in the last year with a price return of +76.1% while the SPY ETF gained +22.0%. However, in the short term, PCVX had mixed performance relative to the market. It has underperformed in the last 3 months, returning +4.2% vs +18.3% return in SPY. But in the last 2 weeks, PCVX shares have fared better than the market returning +16.1% compared to SPY -0.3%.
PCVX support price is $56.37 and resistance is $59.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PCVX shares will trade within this expected range on the day.
